middle.news
Radiopharm Theranostics Advances Clinical Pipeline with $40M Capital Boost
2:52pm on Tuesday 28th of October, 2025 AEDT
•
Healthcare
Read Story
Radiopharm Theranostics Advances Clinical Pipeline with $40M Capital Boost
2:52pm on Tuesday 28th of October, 2025 AEDT
Key Points
FDA IND approval for Phase I Betabart (RV-01) therapeutic trial targeting B7H3
Positive clinical progress across four radiopharmaceutical programs
A$35 million institutional placement plus A$5 million Share Purchase Plan completed
Appointment of Dr Oliver Sartor to Scientific Advisory Board
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE